Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$120,000.00
Assessing the long-term carcinogenic effects of glucagon-like peptide-1 receptor agonists on thyroid, pancreatic, and biliary tract cancers: an international, multi-site cohort study
EF 2024-25
Résumé
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a drug class that has changed the treatment landscape of type 2 diabetes since the mid-2000s. Besides their glucose-lowering effects, this drug class also reduces body mass and provides cardiorenal protection compared to other antihyperglycemic medications (agents that decrease blood glucose levels). In recent years, the increasing demand for some diabetic formulations of GLP-1 RAs (such as Ozempic®) for off-label weight loss has led to shortages worldwide. Despite their beneficial clinical effects, GLP-1 RAs have been the subject of safety concerns over the years, including their potential associations with thyroid, pancreatic, and biliary tract cancers, rare cancers with aggressive forms that are difficult to treat. Previous observational studies that have investigated the association between GLP-1 RAs and thyroid, pancreatic, and biliary tract cancers have major methodological limitations and have yielded mixed results. Furthermore, these studies were conducted when the drugs were fairly new on the market, limiting their follow-up time. As a result, the relationship between GLP-1 RAs and the risks of these cancers remain unclear. Thus, our international, multi-site cohort study aims to assess the potential association between the use of GLP-1 RAs and the risks of thyroid, pancreatic, and biliary tract cancers, separately, among patients with type 2 diabetes. This information will be important to better understanding the safety profile of GLP-1 RAs, which is essential given that these drugs are increasingly prescribed for glycemic control and weight loss.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518929
Name
Lu Sally
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Assessing the long-term carcinogenic effects of glucagon-like peptide-1 receptor agonists on thyroid, pancreatic, and biliary tract cancers: an international, multi-site cohort study
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Epidemiology; Health Intervention; Obesity; Population-Based; Type 2 Diabetes
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a drug class that has changed the treatment landscape of type 2 diabetes since the mid-2000s. Besides their glucose-lowering effects, this drug class also reduces body mass and provides cardiorenal protection compared to other antihyperglycemic medications (agents that decrease blood glucose levels). In recent years, the increasing demand for some diabetic formulations of GLP-1 RAs (such as Ozempic®) for off-label weight loss has led to shortages worldwide. Despite their beneficial clinical effects, GLP-1 RAs have been the subject of safety concerns over the years, including their potential associations with thyroid, pancreatic, and biliary tract cancers, rare cancers with aggressive forms that are difficult to treat. Previous observational studies that have investigated the association between GLP-1 RAs and thyroid, pancreatic, and biliary tract cancers have major methodological limitations and have yielded mixed results. Furthermore, these studies were conducted when the drugs were fairly new on the market, limiting their follow-up time. As a result, the relationship between GLP-1 RAs and the risks of these cancers remain unclear. Thus, our international, multi-site cohort study aims to assess the potential association between the use of GLP-1 RAs and the risks of thyroid, pancreatic, and biliary tract cancers, separately, among patients with type 2 diabetes. This information will be important to better understanding the safety profile of GLP-1 RAs, which is essential given that these drugs are increasingly prescribed for glycemic control and weight loss.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lu, Sally
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~